Trial Profile
Phase 1 Study of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors AnewPharma
- 08 Jan 2020 Planned number of patients changed from 32 to 56.
- 08 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 08 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.